Davidson Zhao

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma

A. Vecchione, Hong Chang, E. Zacksenhaus, 2022, Cancers.

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency

M. Minden, E. Atenafu, J. Capo-Chichi, 2022, Cancer medicine.

NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.

M. Minden, E. Atenafu, J. Capo-Chichi, 2022, Leukemia research.

Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia.

J. Capo-Chichi, Qianghua Zhou, Dennis (Dong Hwan) Kim, 2022, Leukemia research.

Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KITD816V and FLT3-ITD

M. Minden, Hong Chang, J. Capo-Chichi, 2020, Leukemia.

Downregulation of MDM2 Leads to Anti-Proliferative Effects through Activation of p53-Associated Pathway Mediated By Both Dual Inhibitor MX69 and Mir-548c-3p in Multiple Myeloma

Hong Chang, Jian Wu, Min Zhang, 2019, Blood.

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation

M. Minden, E. Atenafu, J. Capo-Chichi, 2023, Cancers.

Impact of secondary‐type mutations in NPM1 mutated AML

Y. W. Yeung, Qianghua Zhou, Hong Chang, 2023, European journal of haematology.

AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

Y. W. Yeung, M. Minden, E. Atenafu, 2023, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.